Vaccine Research International is developing a low-cost vaccine called SA75 to target MRSA infections. SA75 is a whole-cell vaccine produced from inactivated Staph aureus cells that shows cross-reactivity against multiple MRSA strains. Phase I clinical trials in humans showed SA75 was well tolerated and generated an immune response. VRi is seeking further funding to advance R&D and commercialization of SA75, with the goal of out-licensing it to a global pharmaceutical partner.